OSR Holdings Inc (NASDAQ:OSRH) — Market Cap & Net Worth
Market Cap & Net Worth: OSR Holdings Inc (OSRH)
OSR Holdings Inc (NASDAQ:OSRH) has a market capitalization of $12.73 Million ($12.73 Million) as of June 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #26446 globally and #5457 in its home market, demonstrating a -4.55% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying OSR Holdings Inc's stock price $0.38 by its total outstanding shares 33124755 (33.12 Million). Review OSR Holdings Inc (OSRH) total liabilities to assess the company's total debt and financial obligations.
OSR Holdings Inc Market Cap History: 2025 to 2026
OSR Holdings Inc's market capitalization history from 2025 to 2026. Data shows growth from $18.69 Million to $12.73 Million (0.00% CAGR).
OSR Holdings Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how OSR Holdings Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
6.43x
OSR Holdings Inc's market cap is 6.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $18.69 Million | $2.91 Million | -$18.01 Million | 6.43x | N/A |
Competitor Companies of OSRH by Market Capitalization
Companies near OSR Holdings Inc in the global market cap rankings as of June 18, 2026.
Key companies related to OSR Holdings Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #222 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #444 globally with a market cap of $62.63 Billion USD.
- UCB SA (BR:UCB): Ranked #549 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #222 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $458.99 |
| #444 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.63 Billion | $607.93 |
| #549 | UCB SA | BR:UCB | $49.68 Billion | €252.40 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €780.20 |
OSR Holdings Inc Historical Marketcap From 2025 to 2026
Between 2025 and today, OSR Holdings Inc's market cap moved from $18.69 Million to $ 12.73 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $12.73 Million | -31.89% |
| 2025 | $18.69 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 18th, 2026 the market cap of OSR Holdings Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $12.73 Million USD |
| MoneyControl | $12.73 Million USD |
| MarketWatch | $12.73 Million USD |
| marketcap.company | $12.73 Million USD |
| Reuters | $12.73 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About OSR Holdings Inc
OSR Holdings, Inc., a healthcare holding company, develops a portfolio of therapies and healthcare solutions in the United States, Germany, Switzerland, and South Korea. The company develops immunotherapy products, including VXM01, an immuno-oncology candidate for glioblastoma completed phase 2 clinical trial, as well as preclinical stage products, such as VXM04 to treat mesothelin; VXM06 for the… Read more